IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE

The article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the development of this infection with unfavorable outcome. The authors present detailed data on epidemiology and world spread of respiratory-syncytial virus infection, its consequences (short-term and long-term) and prevention possibilities. The authors demonstrate efficacy of passive palivizumab (humanized monoclonal antibody) immune prevention on the basis of multiple studies conducted in different countries. The authors show the process of formation of national recommendations for immune prevention of development of this infection. Apart from the main risk groups for the development of respiratory-syncytial virus infection, acknowledged by the scientists, the authors also present additional groups – children with mucoviscidosis, Down’s syndrome, neuromuscular diseases and immune compromised patients due to the primary immune deficiency or in the setting of immune suppressive therapy.

1. Nair H., Nokes D. J., Gessner B. D. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010; 375 (9725): 1545–1555.

2. Johnson S., Oliver C., Prince G. A. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997; 176: 1215–24.

3. Shay D. K., Holman R. C., Newman R. D. et al. Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA. 1999; 282: 1440–6.

4. Stensballe L. G., Devasundaram J. K., Simoes E. A. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr. Infect. Dis. J. 2003; 22 (2 Suppl.): 21–32.

5. Available at: http://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html

6. Lanari M., Giovannini M., Giuffre L. et al. Investigators RADAR Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr. Pulmonol. 2002; 33: 458–465.

7. Rossi G. A., Medici M. C., Arcangeletti M. C. et al. Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur. J. Pediatr. 2007; 166: 1267–1272.

8. Tatochenko V., Uchaikin V., Gorelov A. et al. Epidemiology of respiratory syncytial virus in children more or about 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin. Epidemiol. 2010 Oct 21; 2: 221–7.

9. Namazova-Baranova L.S., Davydova I.V., Turti T.V. Farmateka dlya praktikuyushchikh vrachei = Pharmateca for practicing physicians. 2013; 1: 51–55.

10. Otchet «Monitoring RS-virusnoi infektsii sredi detei 0–2 let po dannym traditsionnogo i signal'nogo nadzora za period s 52 nedeli 2012 g. po 17 nedelyu 2013 g. FGBU «NII grippa» Minzdrava Rossii [The Report "Monitoring of RS-Virus Infection among Children of 0-2 years according to the Traditional Signaling and Supervision for the Period from 52nd week of 2012 to 17th week of 2013 FSBI "Influenza Research Institute” of Russian Ministry of Health]. St.Petersburg, 2013.

11. Stockman L. J., Curns A. T., Anderson L. J. et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. The Pediatric Infectious Disease Journal. 2012; 31 (1): 5–9.

12. Bourgeois F. T., Valim C., McAdam A. J. et al. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009; 124 (6): 1072–80.

13. Thompson W. W., Shay D. K., Weintraub E. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289: 179–186.

14. Ovsyannikov D. Yu. Acute bronchiolitis in children. Voprosy prakticheskoi pediatrii = Current pediatrics. 2010; 5 (2): 75–84.

15. Welliver R. C., Checchia P. A., Bauman J. H. et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Current Medical Research and Opinion. 2010; 26 (9): 2175–2181.

16. Holman R. C., Shay D. K., Curns A. T. et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr. Infect. Dis. J. 2003; 22: 483–490.

17. Boukhvalova M. S., Prince G. A., Soroush L. et al. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine–enhanced disease. Vaccine. 2006; 24 (23): 5027–5035.

18. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997; 99 (1): 93–99.

19. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998; 102 (3 Pt. 1): 531–537.

20. Feltes T. F., Cabalka A. K., Meissner H. C. et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J. Pediatr. 2003; 143 (4): 532–540.

21. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J. et al. Iris Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalisations in premature infants. Pediatr. Infect. Dis. J. 2003; 22 (9): 823–827.

22. Checchia P. A., Nalysnyk L., Fernandes A. W. et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr. Crit. Care Med. 2011; 12 (5): 580–588.

23. Sampalis J. S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J. Pediatr. 2003; 143 (5 Suppl.): 150–156.

24. Sigurs N., Aljassim F., Kjellman B. et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010; 65 (12): 1045–1052.

25. Simoes E. A. F., Groothuis J. R., Carbonell-Estrany X. et al. Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing. J. Pediatr. 2007; 151: 34–42.

26. Blanken M. O., Rovers M. M., Molenaar J. M. et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368 (19): 1791–1799.

27. Ibara S. Expanding boundaries: new risk groups for RSV prevention. XI World Congress of Perinatal Medicine. Moscow. 2013.

28. Figueras-Aloy J., Carbonell-Estrany X., Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr. Infect. Dis. J. 2004; 23 (9): 815–820.

29. Figueras-Aloy J., Carbonell-Estrany X., Quero-Jimenez J. et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr. Infect. Dis .J. 2008; 27 (9): 788–793.

30. Hall C. B., Powell K. R., MacDonald N. E. et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 1986; 315 (2): 77–81.

31. Manzoni P., Leonessa M., Farina D. et al. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting. Pediatr. Transplant. 2007; 11 (4): 456–457.

32. Michaels M. G., Fonseca-Aten M., Green M. et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr. Transplant. 2009; 13 (4): 451–456.

33. Hiatt P. W., Grace S. C., Kozinetz C. A. et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999; 103 (3): 619–626.

34. Giebels K., Marcotte J-E., Podoba J. et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr. Pulmonol. 2008; 43 (2): 169–174.

35. Tomilova A.Yu., Namazova-Baranova L.S., Alekseeva A.A., Davydova I.V., Gevorkyan A.K., Vishneva E.A., Voznesenskaya N.I. Opyt primeneniya palivizumaba u bol'noi s mukovistsidozom. V Rossiiskii Forum «Pediatriya Sankt-Peterburga: opyt, innovatsii, dostizheniya. Sankt-Peterburg–2013». Sbornik tezisov [Experience of Palivizumab Application in a Patient with Cystic Fibrosis. 5th Russian Forum "St. Petersburg’s Pediatrics: Experience, Innovations and Achievements. St. Petersburg-2013 ". Collection of Abstracts.]. St. Petersburg, 2013. p. 119.

36. Megged O., Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 2010; 29 (7): 672–673.

37. Resch B., Manzoni P., Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr. Respir. Rev. 2009; 10 (3): 148–153.

38. From the American Academy of Pediatrics: Policy statements = Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124 (6): 1694–701.

39. Turti T. V., Baibarina E. N., Degtiareva E. A. et al. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Research Notes. 2012; 5: 484.

40. Namazova-Baranova L.S., Vishneva E.A., Torshkhoeva R.M., Kulichenko T.V., Tomilova A.Yu., Alekseeva A.A., Turti T.V. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (3): 24–30.

41. Korsunskii A. A., Ovsyannikov D. Yu., Degtyarev D. N. et al. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (3): 22–30.

42. Rudakova A. V., Babachenko I. V., Rovnyi V. B. et al. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11 (4): 80–84.

43. Davydova I. V., Turti T. V., Namazova-Baranova L. S. et al. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (6): 48–52.